Alternatively, we tested ralimetinib, an effective p38 inhibitor, used for the treatment of metastatic breast cancer and other advanced cancer types in phase II clinical trials, alone or in combination with currently available therapeutic modalities [34,43]. Here, MAPK14 is linked to cancer.